Allogene Therapeutics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Allogene Therapeutics Stock Summary

Allogene Therapeutics competes with Heron Therapeuti, Annexon, Sangamo Therapeutics, Beam Therapeutics, and Sana Biotechnology. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 344 people.

Allogene Therapeutics Key Financial Ratios

Allogene Therapeutics Key Balance Sheet Accounts

Allogene Therapeutics Key Income Statement Accounts

Allogene Therapeutics Key Cash Accounts

Allogene Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Allogene Therapeutics's current stock value. Our valuation model uses many indicators to compare Allogene Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Allogene Therapeutics competition to find correlations between indicators driving Allogene Therapeutics's intrinsic value. More Info.Allogene Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Allogene Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Allogene Therapeutics' earnings, one of the primary drivers of an investment's value.

Allogene Therapeutics Systematic Risk

Today, most investors in Allogene Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Allogene Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Allogene Therapeutics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Allogene Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Allogene Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Allogene Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Allogene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Allogene Therapeutics's daily price indicators and compare them against related drivers.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.